Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitts Leukemia/Lymphoma|Chronic Myelogenous Leukemia
DRUG: CLAG-M|DRUG: CLAG-M
Complete remission percentage, 1 month
Survival, 2 years
Patients will receive standard dose CLAG-M (cladribine, cytarabine, mitoxantrone, filgrastim). Standard support care will be given. Efficacy will be assessed through bone marrow examinations and blood tests.